Creating smarter ways to fight bacteria

Leading the advancement of technologies and products that break up biofilms and destroy bacteria.
For over 20 years Kane Biotech’s R+D division has been developing new technologies and innovations leading to 80 patents and patents pending in biotechnology focusing primarily on biofilm.
About Us Research & Development
80
80

Patents and Patents Pending

STEM Animal Health

Kane’s first Commercialization Vehicle formed in partnership with Animalcare Group, STEM Animal Health is a new animal health company dedicated to targeting biofilm-related ailments.

Learn More

Kane Wound Care & Surgical

Biofilms are pervasive and represent the most prevalent bacterial mode of growth. The current wound care global market is expected to reach US $22 billion by 2022.

Learn More

Kane Dermatology

The strategic focus of the Kane Dermatology subsidiary is to develop and sell non-prescription consumables to end customers that address minor health ailments where biofilms contribute to the problem.

Learn More

Understanding Biofilms

The study of biofilms has increased significantly in recent years due to the growing awareness of the pervasiveness and impact of biofilms on human and animal health, as well as natural and industrial systems.

Learn About Biofilms
Kane Wound & Surgical Care Feature

coactiv+™ Antimicrobial Wound Gel

Why would you use any other wound gel?

  • The coactiv+™ Wound Gel is a combination of Kane’s patented coactiv+™ antibiofilm technology in a thermo-reversible gel that provides a moist environment best suited for wound healing.
  • Thermo-reversible gels, like coactiv+ Wound Gel, undergo a reversible transformation from liquid to gel with temperature. At room temperature, coactiv+™ Wound Gel appears in a gel state, allowing for easy application onto wounds, including burns. Below 20 degrees Celsius (or in cold water), the gel transforms into a liquid state and can be easily removed from the skin.
  • Accessible for patients. The coactiv+™ Wound Gel fits within reimbursement of US $19.88/oz with US $59.64/3oz for the monthly allowable - one of the ONLY wound gels within reimbursement.
View coactiv+™ Video

Renderings shown are for illustrations purpose only.
These drawings are not meant to be an exact rendition.

STEM Animal Health Feature

Pet Specialty Market

Kane Biotech’s bluestem™ brand of pet oral care products are scientifically formulated with Kane’s patented coactiv+™ technology to safely break down plaque and tartar biofilm and freshen breath.

Learn More

Veterinary Market

STEM Pet Oral Care line is licensed globally for the Veterinary Market, through Dechra in North & South America, and Animalcare Group in the rest of the world.

Learn More

VOHC Acceptance

STEM Animal Health received VOHC acceptance in 2022 as Kane’s coactiv+™ technology was proven to significantly reduce accumulation of tartar.

Learn More
Kane Dermatology Feature

DermaKB™

A new scalp detoxifier and shampoo designed to break down biofilm.

Recent research has indicated that the persistence of biofilms may be linked with aggravating the symptoms associated with common scalp conditions, such as dandruff and seborrheic dermatitis.

Kane Dermatology launched a shampoo, shampoo bar and scalp detoxifier under the DermaKB™ brand as the first products in their new skin care line. The products are sold direct-to-consumer through Amazon and Kane’s online commerce site.

Kane had conducted an extensive consumer trial on DermaKB™ scalp care products with coactiv+™ across North America with 4,500 participants suffering from a variety of common scalp conditions. Over 1,400 extensive questionnaires were completed, and of the participants who used both the DermaKB™ Detoxifier and Shampoo and rated their symptom as either extreme or severe before the trial, 82% identified an improvement in their symptom after using the products.

From Our Video Library

View our collection of videos on everything from business updates to industry webinars.

2022 Video Blog Series

As part of our commitment to communicate more frequently with our investors in 2022, Kane Biotech Inc. introduces a new video blog series, with each video focused on one important topic that is driving our business forward.

Watch The Video Series

Kane Biotech Video Archive

From business update series to industry webinars, Kane Biotech has a number of past videos to watch at your leisure.

Watch Past Videos

The Latest Articles from Our Kane Blog

Click the images or titles below to read the full articles.

  • T.I.M.E. Assessment to Treat Wounds Impacted by Biofilms
    par Kane Biotech le novembre 30, 2022 à 9:21

    As researchers continue to study the impacts of biofilms on wounds, individuals living with chronic wounds often experience a negative impact on their overall physical and mental health, especially for those whose wounds continue for months or even years. Chronic wound patients commonly report concerns

  • Kane Biotech Announces Achievements in October 2022
    par Kane Biotech le novembre 8, 2022 à 3:40

    Kane Biotech experienced significant achievements in October 2022, for both their coactiv+™ and their DispersinB® technologies. For over 20 years, Kane has been developing new technologies and innovations, leading to 80 patents and patents pending in biotechnology focusing primarily on biofilm. Kane Biotech Announces 510(k)

  • Antibiotic Resistance & Biofilms: The Next Pandemic
    par Kane Biotech le octobre 18, 2022 à 2:31

    Antimicrobial resistance (AR) occurs when bacteria are exposed to levels of antibiotics that fail to kill the bacteria. For example, when an antibiotic that was able to treat an infection previously is no longer able to effectively kill bacteria, and results in an ongoing or

  • Biofilm: Protector of Bacteria & Fungi
    par Kane Biotech le octobre 4, 2022 à 5:59

    The National Institute of Health reports that 80% of all known human infections are associated with biofilms. Biofilms are a serious and urgent clinical and financial burden to health care systems and patients, costing industry, cities, and hospitals over $500 billion each year. What are

  • Biofilms: Their Goal is to Keep You Sick
    par Kane Biotech le septembre 13, 2022 à 4:35

    If you have never heard of biofilms before, you are not alone. Biofilms may be an uncommon word, but they impact our lives and health in many ways – including keeping us sick. A simple way to describe a biofilm is it being a glue-like

View All Articles

Investor Relations

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

View Kane Biotech’s latest financial reports, press releases, and presentations to provide you with insight into our business and investor relations.

Corporate News Investor Section

Our Location

Kane Biotech’s offices and laboratories are located in the University of Manitoba Smartpark Innovation Hub. It includes two independent analytical laboratories and three independent and well-equipped microbiology suites.

Click on the Matterport links to take an immersive 3D virtual tour of Kane Biotech’s offices and laboratories.

Matterport 360° Office Tour Matterport 360° Lab Tour